Merck (MRK) Cost of Revenue (2009 - 2026)

Merck (MRK) has reported Cost of Revenue for 18 consecutive years, with $4.2 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue rose 22.7% year-over-year to $4.2 billion; the TTM figure through Mar 2026 stood at $17.2 billion (up 13.84% YoY), while the FY2025 annual figure was $16.4 billion, up 7.83% from the prior year.
• Cost of Revenue fell to $4.2 billion in Q1 2026 per MRK's latest filing, from $5.6 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $5.6 billion in Q4 2025 and bottomed at $3.4 billion in Q1 2025.
• Historically, Cost of Revenue has averaged $4.1 billion across 5 years, with a median of $3.9 billion in 2023.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 68.18% — and 2023, when it dropped 27.03%.
• Merck's Cost of Revenue stood at $3.9 billion in 2022, then increased by 0.8% to $3.9 billion in 2023, then retreated by 2.15% to $3.8 billion in 2024, then jumped by 45.01% to $5.6 billion in 2025, then decreased by 24.43% to $4.2 billion in 2026.
• Business Quant data shows MRK's Cost of Revenue at $4.2 billion in Q1 2026, $5.6 billion in Q4 2025, and $3.9 billion in Q3 2025.